Company: MYSEW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001013762-25-004290
Chunk: 753

Company: Myseum, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 4
Chunk 753
---
2025, the Company granted an aggregate of 230,000 options
to purchase the Company’s common stock to an officer, employees and consultants of the Company. The options each have a term of
10 years from the date of grant and are exercisable at an exercise price of $5.50 per share. The options vest in equal 25% installments
every 6 months beginning on the 6-month anniversary of the date of grant. The stock options were valued at the grant date using a Black-Scholes
option pricing model which will be recognized as stock-based compensation expense over the vesting period.

Equity Sales Agreement

On February 10, 2025, the Company entered into a Sales Agreement (the
“Sales Agreement”) with The Benchmark Company, LLC (“Benchmark”) to sell shares of the Company’s common
shares (the “Shares”) having an aggregate sales price of up to $6,000,000, from time to time, through an “at the market
offering” program under which Benchmark will act as sales agent. The sales, if any, of the Shares made under the Sales Agreement
will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgated under
the Securities Act of 1933, as amended.

The Company will pay Benchmark a commission rate equal to 4.0% of the
aggregate gross proceeds from each sale of Shares; provided however, that in the event that the amount of Shares sold under the Sales
Agreement increases to $1 million or more, then the commission rate will be reduced to 3%. In addition, the Company agreed to provide
Benchmark with customary indemnification and contribution rights. The Company will also reimburse Benchmark for certain specified expenses
in connection with entering into the Sales Agreement. The Sales Agreement contains customary representations and warranties and conditions
to the sale of the Shares pursuant thereto. The Company is not obligated to sell any of the Shares under the Sales Agreement and may at
any time suspend solicitation and offers thereunder. The offering of Shares pursuant to the Sales Agreement will terminate on the earlier
of (1) the sale, pursuant to the Sales Agreement, of Shares having an aggregate offering price of $6,000,000 and (2) the termination
of the Sales Agreement by either us or Benchmark, as permitted therein. The Shares will be issued pursuant to our shelf registration statement
on Form S-3 (File